Recursion Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $26,082 | $14,417 | $13,794 | $10,891 |
Gross Profit | 14,003 | 1,318 | -772 | -12,590 |
EBITDA | -87,924 | -89,669 | -84,732 | -93,514 |
EBIT | -95,122 | -97,669 | -92,132 | -109,130 |
Net Income | -95,675 | -97,540 | -91,373 | -92,996 |
Net Change In Cash | 26,082 | 14,417 | 13,794 | 10,891 |
Free Cash Flow | -60,787 | -86,401 | -108,953 | -76,494 |
Cash | 427,647 | 476,124 | 299,521 | 394,796 |
Basic Shares | 282,583 | 242,196 | 236,019 | 233,158 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $44,575 | $39,681 | $10,000 | $3,413 |
Gross Profit | 1,988 | -8,594 | 10,000 | -59,906 |
EBITDA | -299,566 | -233,971 | -174,370 | -81,703 |
EBIT | -323,968 | -245,727 | -182,775 | -86,145 |
Net Income | -328,066 | -239,421 | -178,074 | -87,882 |
Net Change In Cash | 44,575 | 39,681 | 10,000 | 3,413 |
Cost of Revenue | 28,182 | |||
Free Cash Flow | -300,332 | -120,883 | -198,412 | -52,134 |
Cash | 391,565 | 549,912 | 285,116 | 262,126 |
Basic Shares | 207,853 | 175,537 | 170,272 | 165,791 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.34 |
2024-06-30 | -$0.40 |
2024-03-31 | -$0.39 |
2023-12-31 | -$0.42 |
